Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NextCOVE: mRNA-1283 vs mRNA-1273 for COVID-19 Prevention
NCT05815498Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Mar 2023
- Primary completion
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 4
01
Overview
A Phase 3 trial of mRNA-1283.251 in coronavirus disease 2019 (COVID-19), sponsored by Moderna Inc. Started Mar 2023; status: completed.
02
Drugs
mRNA-1283.251
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05815498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05815498.